PC
NRXP icon

Periscope Capital’s NRX Pharmaceuticals NRXP Stock Holding History

Periscope Capital’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-25,180
Closed -$2.57M – 181
2018
Q4 		$2.57M Sell
25,180
-20
-0.1% -$2.02K 0.48% 78
2018
Q3 		$2.53M Hold
25,200
– – 0.48% 79
2018
Q2 		$2.5M Buy
25,200
+10,080
+67% +$995K 0.53% 74
2018
Q1 		$1.49M Buy
15,120
+10,080
+200% +$983K 0.35% 82
2017
Q4 		$490K Buy
+5,040
New +$487K 0.12% 90

Other funds holding NRXP

OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Periscope Capital's NRXP Position: Q1 2019 in Review

Periscope Capital sold out of NRX Pharmaceuticals (NRXP) in Q1 2019, closing a stake of 25,180 shares — an estimated $2.57M sold.

Periscope Capital first reported a position in NRXP in Q4 2017 and held it in 5 quarters. The position peaked at $2.57M in Q4 2018. 20 funds tracked by Wall St. Rank hold NRXP as of Q1 2019.

  • Periscope Capital reported no remaining NRX Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Periscope Capital sold 25,180 NRX Pharmaceuticals shares in Q1 2019, an estimated $2.57M.
  • Periscope Capital first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Periscope Capital's NRX Pharmaceuticals position peaked at $2.57M in Q4 2018.
  • 20 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2019.

Based on Periscope Capital's 13F filing for Q1 2019, filed 2 May 2019.